BG Medicine Inc. (Nasdaq: BGMD) narrowed fourth quarter losses more than expected to 6 cents per share from 14 cents per share in the year ago period and announced the receipt of a patent for Galectin-3 and cardiac resynchronization therapy. The stock price soared 49 cents to $2.18.
BG Medicine Receives Patent
March 20, 2014 at 06:05 AM EDT
